➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
Johnson and Johnson
Dow
Colorcon

Last Updated: May 29, 2020

DrugPatentWatch Database Preview

Bevacizumab - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for bevacizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 3
Elizabeth BuchbinderPhase 2
Shanghai Zhongshan HospitalPhase 2

See all bevacizumab clinical trials

Recent Litigation for bevacizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
Genentech, Inc. v. Pfizer Inc.2019-04-05
Genentech, Inc. v. Immunex Rhode Island Corp.2019-03-29

See all bevacizumab litigation

PTAB Litigation
PetitionerDate
2018-01-08
2018-01-05
2017-11-17

See all bevacizumab litigation

Company Disclosures: US Patents for bevacizumab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Biogen, Inc. (Cambridge, MA) 2020-08-05 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Biogen, Inc. (Cambridge, MA) 2020-08-05 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for bevacizumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for bevacizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90004-6 Sweden   Start Trial PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808
C/GB06/025 United Kingdom   Start Trial PRODUCT NAME: NATALIZUMAB, ANTI -4 INTEGRIN HUMANIZED MONOCLONAL ANTIBODY; REGISTERED: UK EU/1/06/346/001 20060627
271 Luxembourg   Start Trial PRODUCT NAME: NATALIZUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES ( TYSABRI ); AUTHORISATION NUMBER AND DATE: EU/1/06/346/001
2016000070123 Italy   Start Trial PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
642 Luxembourg   Start Trial PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805
C 025/2006 Ireland   Start Trial SPC 025/2006: 20070523, EXPIRES: 20200124
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Moodys
McKesson
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.